复星医药成员企业桂林南药泊沙康唑获批上市

复星医药
22 Jul

近日,复星医药成员企业桂林南药的新产品泊沙康唑原料药成功获得国家药品监督管理局(NMPA)批准上市,这是桂林南药今年首个通过自主申报并获得注册证书的新产品。泊沙康唑类别为抗真菌药,可制成包括肠溶片及注射剂在内的多种剂型。 此次获批不仅标志着该原料药达到了严格的药品质量标准,更为公司后续开发泊沙康唑相关制剂产品(如肠溶片、注射液等)奠定了坚实的物质基础与质量保障,对丰富公司抗感染药物管线、满足临床...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10